Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $22.38 (market cap $249.48B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 9.9× Royalty Pharma plc Class A Ordinary Shares's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays the higher dividend (2.4%). Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MUFG | RPRX | |
|---|---|---|
Market Cap | $249.48B | $25.27B |
Volume | 4,008,160 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $24.13 | $63.96 |
52-Week Low | $14.62 | $35.44 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $28.96T | $32.50B |
Dividend Yield | 2.4% | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
